|
Mammalian cell cytotoxicity test in chinese hamster V79 cells (clonogenic cytotoxicity)
|
None
|
380.0
ug.mL-1
|
|
Mammalian cell cytotoxicity test in chinese hamster V79 cells (clonogenic cytotoxicity)
|
None
|
380.0
ug.mL-1
|
|
Mammalian cell cytotoxicity test in chinese hamster V79 cells (clonogenic cytotoxicity)
|
None
|
380.0
ug.mL-1
|
|
|
Compound evaluated in vitro for the ability to inhibit gyrase.
|
None
|
5.3
ug.mL-1
|
|
|
Inhibitory activity against DNA gyrase enzyme was determined by supercoiling assay with Escherichia coli DNA gyrase
|
Escherichia coli
|
500.0
nM
|
|
|
Inhibition of the gyrase mediated cleavage of supercoiled DNA
|
Escherichia coli
|
5.3
ug.mL-1
|
|
|
Effect on replication DNA biosynthesis in Escherichia coli H560 (permeabilised cells)
|
Escherichia coli
|
0.3
ug.mL-1
|
|
|
Supercoiling inhibition assay using purified DNA gyrase isolated from Escherichia coli H560
|
Escherichia coli
|
0.9
ug.mL-1
|
|
|
Inhibitory activity against gyrase supercoiling activity from Escherichia coli
|
Escherichia coli
|
0.68
ug.mL-1
|
|
|
Inhibitory activity on replicative DNA biosynthesis in Escherichia coli H560 (permeabilised cells)
|
Escherichia coli
|
0.3
ug.mL-1
|
|
|
Inhibition of [3H]muscimol binding to GABA A receptor 4-biphenylacetic acid at 10 e-4 M
|
None
|
410.0
nM
|
|
|
Inhibitory concentration in supercoiling inhibition Escherichia coli DNA gyrase assay
|
Escherichia coli
|
5.3
ug.mL-1
|
|
|
50% inhibitory concentration against DNA-gyrase
|
Escherichia coli
|
5.3
ug.mL-1
|
|
|
Gyrase inhibitory activity against Escherichia coli
|
Escherichia coli
|
0.3
ug.mL-1
|
|
|
Inhibition of Quinolone resistant gyrase Supercoiling Activity in Escherichia coli
|
Escherichia coli
|
102.4
ug.mL-1
|
|
|
Inhibition of Wild Type DNA gyrase Supercoiling Activity in Escherichia coli
|
Escherichia coli
|
1.6
ug.mL-1
|
|
|
Inhibitory effect against Escherichia coli Gyrase in Supercoiling assay
|
Escherichia coli
|
0.68
ug.mL-1
|
|
|
Cytotoxicity was determined for the compound in HepG2 cell line
|
Homo sapiens
|
37.47
ug.mL-1
|
|
|
Inhibitory concentration against Mycobacterium intracellular
|
Mycobacterium intracellulare
|
0.25
ug.mL-1
|
|
|
Inhibitory concentration against Staphylococcus aureus; Not active
|
Staphylococcus aureus
|
0.1
ug.mL-1
|
|
|
Inhibitory concentration against methicillin-resistant Staphylococcus aureus
|
Staphylococcus aureus
|
0.1
ug.mL-1
|
|
|
Inhibitory activity against HeLa cell Topoisomerase II
|
None
|
30.0
nM
|
|
|
Clonogenic cytotoxicity against Hamster V-79 cells
|
Cricetulus griseus
|
200.0
ug.mL-1
|
|
|
Clonogenic cytotoxicity against Chinese hamster V-79 cells
|
Cricetulus griseus
|
320.0
ug.mL-1
|
|
|
Cytotoxicity was determined for the compound in V79-4 cell line
|
Cricetulus griseus
|
58.55
ug.mL-1
|
|
|
Inhibition of supercoiling activity of DNA gyrase from Staphylococcus aureus ISP 794
|
Staphylococcus aureus
|
5.0
ug.mL-1
|
|
|
Inhibitory concentration against DNA gyrase of Staphylococcus aureus
|
Staphylococcus aureus
|
20.1
ug.mL-1
|
|
|
Inhibition of supercoiling activity of topoisomerase IV from Staphylococcus aureus ISP 794; Range = 2.5-5 ug/mL
|
Staphylococcus aureus
|
5.0
ug.mL-1
|
|
|
In vitro inhibitory concentration against DNA gyrase from Escherichia coli H560
|
Escherichia coli
|
3.1
ug.mL-1
|
|
|
Antimycobacterial activity of compound against Mycobacterium tuberculosis H37Rv at 2 ug/mL
|
Mycobacterium tuberculosis
|
95.0
%
|
|
|
Inhibition of DNA gyrase supercoiling in Escherichia coli ATCC 25922
|
Escherichia coli
|
300.0
nM
|
|
|
Inhibition of Bacillus subtilis topoisomerase4 activity
|
Bacillus subtilis
|
1.9
ug.mL-1
|
|
|
Inhibition of Bacillus subtilis gyrase activity
|
Bacillus subtilis
|
0.74
ug.mL-1
|
|
|
Inhibitory activity against wild type Escherichia coli gyrase
|
Escherichia coli
|
300.0
nM
|
|
|
Inhibition of Escherichia coli gyrase
|
Escherichia coli
|
200.0
nM
|
|
|
Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs
|
Homo sapiens
|
170.0
ug.mL-1
|
|
|
Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs
|
Homo sapiens
|
400.0
ug.mL-1
|
|
|
Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs
|
Homo sapiens
|
160.0
ug.mL-1
|
|
|
Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs
|
Homo sapiens
|
150.0
ug.mL-1
|
|
|
Antiproliferative effect against HeLa cells after 48 hrs
|
Homo sapiens
|
290.0
ug.mL-1
|
|
|
Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs
|
Homo sapiens
|
120.0
ug.mL-1
|
|
|
Antibacterial activity against methicillin-resistant Staphylococcus aureus
|
Staphylococcus aureus
|
0.1
ug.mL-1
|
|
|
Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 after 18 to 24 hrs
|
Staphylococcus aureus
|
0.09
ug.mL-1
|
|
|
Antibacterial activity against Mycobacterium intracellular ATCC 23068 after 68 to 72 hrs
|
Mycobacterium intracellulare
|
0.3
ug.mL-1
|
|
|
Antibacterial activity against Mycobacterium intracellular ATCC 23068
|
Mycobacterium intracellulare
|
0.35
ug.mL-1
|
|
|
Antimycobacterial activity against Mycobacterium tuberculosis H37Rv
|
Mycobacterium tuberculosis
|
10.0
ug.mL-1
|
|
|
Antimycobacterial activity against Mycobacterium tuberculosis H37Rv at 6.25 ug/mL
|
Mycobacterium tuberculosis
|
98.0
%
|
|
|
Antimicrobial activity against Mycobacterium intracellular ATCC 23068
|
Mycobacterium intracellulare
|
420.0
nM
|
|
|
Inhibition of Escherichia coli H560 DNA gyrase assessed as DNA cleavage
|
Escherichia coli
|
400.0
nM
|
|
|
Antibacterial activity against methicillin-resistant Staphylococcus aureus
|
Staphylococcus aureus
|
0.08
ug.mL-1
|
|
|
Inhibition of Mycobacterium leprae recombinant DNA gyrase expressed in Escherichia coli assessed as inhibition of pBR322 DNA supercoiling
|
Mycobacterium leprae
|
3.5
ug.mL-1
|
|
|
Antimicrobial activity against Staphylococcus aureus
|
Staphylococcus aureus
|
0.1
ug.mL-1
|
|
|
Antibacterial activity against methicillin-resistant Staphylococcus aureus
|
Staphylococcus aureus
|
0.1
ug.mL-1
|
|
|
Antibacterial activity against Mycobacterium intracellular
|
Mycobacterium intracellulare
|
0.25
ug.mL-1
|
|
|
Antimicrobial activity against Staphylococcus aureus
|
Staphylococcus aureus
|
0.07
ug.mL-1
|
|
|
Antimicrobial activity against methicillin-resistant Staphylococcus aureus
|
Staphylococcus aureus
|
0.1
ug.mL-1
|
|
|
Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 43300
|
Staphylococcus aureus
|
300.0
nM
|
|
|
Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 43300
|
Staphylococcus aureus
|
0.06
ug.mL-1
|
|
|
Antimicrobial activity against Mycobacterium intracellular ATCC 23068
|
Mycobacterium intracellulare
|
0.25
ug.mL-1
|
|
|
Inhibition of Escherichia coli DNA gyrase
|
Escherichia coli
|
400.0
nM
|
|
|
Antimicrobial activity against Staphylococcus aureus ATCC 29213 by modified NCCLS method
|
Staphylococcus aureus
|
0.15
ug.mL-1
|
|
|
Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 by modified NCCLS method
|
Staphylococcus aureus
|
0.1
ug.mL-1
|
|
|
Antimicrobial activity against Mycobacterium intracellular by Alamar blue assay
|
Mycobacterium intracellulare
|
0.45
ug.mL-1
|
|
|
Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 by antimicrobial susceptibility test
|
Staphylococcus aureus
|
0.1
ug.mL-1
|
|
|
Antimicrobial activity against Mycobacterium intracellular ATCC 23068 by alamar blue method
|
Mycobacterium intracellulare
|
0.4
ug.mL-1
|
|
|
Antibacterial activity against Staphylococcus aureus
|
Staphylococcus aureus
|
0.1
ug.mL-1
|
|
|
Antibacterial activity against methicillin-resistant Staphylococcus aureus
|
Staphylococcus aureus
|
0.1
ug.mL-1
|
|
|
Antibacterial activity against Mycobacterium intracellular by alamar blue assay
|
Mycobacterium intracellulare
|
0.25
ug.mL-1
|
|
|
Antifungal activity against Mycobacterium intracellular ATCC 23068 at 37 degC after 68 to 72 hrs
|
Mycobacterium intracellulare
|
0.3
ug.mL-1
|
|
|
Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 after 18 to 24 hrs
|
Staphylococcus aureus
|
300.0
nM
|
|
|
Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 by NCCLS method
|
Staphylococcus aureus
|
0.1
ug.mL-1
|
|
|
Antimicrobial activity against Mycobacterium intracellular ATCC 23068 by alamar blue assay
|
Mycobacterium intracellulare
|
0.25
ug.mL-1
|
|
|
Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 after 18 to 24 hrs by alamar blue assay
|
Staphylococcus aureus
|
400.0
nM
|
|
|
Antibacterial activity against Staphylococcus aureus ATCC 29213 by alamar blue assay
|
Staphylococcus aureus
|
400.0
nM
|
|
|
Antibacterial activity against Escherichia coli ATCC 35218 after 18 to 24 hrs by alamar blue assay
|
Escherichia coli
|
10.0
nM
|
|
|
Antibacterial activity against Pseudomonas aeruginosa ATCC 9027
|
Pseudomonas aeruginosa
|
1.18
ug.mL-1
|
|
|
Antibacterial activity against Staphylococcus aureus ATCC 29213 by modified CLSI/NCCLS method
|
Staphylococcus aureus
|
360.0
nM
|
|
|
Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 by modified CLSI/NCCLS method
|
Staphylococcus aureus
|
360.0
nM
|
|
|
Antibacterial activity against Escherichia coli ATCC 35218 by modified CLSI/NCCLS method
|
Escherichia coli
|
10.0
nM
|
|
|
Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 by modified CLSI/NCCLS method
|
Pseudomonas aeruginosa
|
220.0
nM
|
|
|
Inhibition of Staphylococcus aureus wild type DNA topoisomerase 4
|
Staphylococcus aureus
|
1.24
ug.mL-1
|
|
|
Inhibition of Staphylococcus aureus DNA topoisomerase 4 Ser80Phe mutant
|
Staphylococcus aureus
|
22.4
ug.mL-1
|
|
|
Inhibition of Staphylococcus aureus wild type DNA gyrase
|
Staphylococcus aureus
|
13.4
ug.mL-1
|
|
|
Inhibition of Staphylococcus aureus DNA gyrase Ser84Leu mutant
|
Staphylococcus aureus
|
256.0
ug.mL-1
|
|
|
Antimycobacterial activity against Mycobacterium intracellular ATCC 23068
|
Mycobacterium intracellulare
|
0.3
ug.mL-1
|
|
|
Antibacterial activity against Mycobacterium intracellular by after 4 days alamar blue assay
|
Mycobacterium intracellulare
|
910.0
nM
|
|
|
Antibacterial activity against methicillin-resistant Staphylococcus aureus by NCCLS method
|
Staphylococcus aureus
|
0.1
ug.mL-1
|
|
|
Antibacterial activity against Staphylococcus aureus by NCCLS method
|
Staphylococcus aureus
|
0.1
ug.mL-1
|
|
|
Antimicrobial activity against methicillin resistant Staphylococcus aureus ATCC 43300
|
Staphylococcus aureus
|
140.0
nM
|
|
|
Antimicrobial activity against methicillin resistant Mycobacterium intracellular ATCC 23068
|
Mycobacterium intracellulare
|
470.0
nM
|
|
|
Antimicrobial activity against Staphylococcus aureus ATCC 29213 by CLSI method
|
Staphylococcus aureus
|
0.09
ug.mL-1
|
|
|
Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 by CLSI method
|
Staphylococcus aureus
|
0.05
ug.mL-1
|
|
|
Inhibition of Escherichia coli DNA gyrase-mediated supercoiling of pBR322 using bromothymol blue by electrophoresis
|
Escherichia coli
|
0.34
ug.mL-1
|
|
|
Inhibition of Escherichia coli DNA topoisomerase-4-mediated decatenation of pBR322 by electrophoresis
|
Escherichia coli
|
4.6
ug.mL-1
|
|
|
Antibacterial activity against ciprofloxacin-resistant Salmonella enteritidis 104 harboring gyrA D87Y/S83F mutant, soxR R20H mutant and soxS E52K mutant gene assessed as reduction in swim motility after overnight incubation
|
Salmonella enterica subsp. enterica serovar Enteritidis
|
66.0
%
|
|
|
Antibacterial activity against ciprofloxacin-susceptibility revert strain of Salmonella enteritidis 104 harboring gyrA D87Y/S83F mutant, parC D79N mutant, soxR E16G/R20H mutant and soxS E52K mutant gene assessed as reduction in swim motility after overnight incubation
|
Salmonella enterica subsp. enterica serovar Enteritidis
|
90.0
%
|
|
|
Antibacterial activity against ciprofloxacin-resistant Salmonella enteritidis 5408 harboring gyrA D87Y mutant, gyrB E466D mutant, parE V461G mutant and ramR G25A mutant gene assessed as reduction in swim motility after overnight incubation
|
Salmonella enterica subsp. enterica serovar Enteritidis
|
93.0
%
|
|
|
Antibacterial activity against ciprofloxacin-resistant Salmonella enteritidis 104 harboring gyrA D87Y/S83F mutant, soxR R20H mutant and soxS E52K mutant gene assessed as reduction in swarm motility after overnight incubation
|
Salmonella enterica subsp. enterica serovar Enteritidis
|
36.0
%
|
|
|
Antibacterial activity against ciprofloxacin-resistant Salmonella enteritidis 5408 harboring gyrA D87Y mutant, gyrB E466D mutant, parE V461G mutant and ramR G25A mutant gene assessed as reduction in swarm motility after overnight incubation
|
Salmonella enterica subsp. enterica serovar Enteritidis
|
46.0
%
|
|
|
Antibacterial activity against ciprofloxacin-susceptibility revert strain of Salmonella enteritidis 104 harboring gyrA D87Y/S83F mutant, parC D79N mutant, soxR E16G/R20H mutant and soxS E52K mutant gene assessed as reduction in swarm motility after overnight incubation
|
Salmonella enterica subsp. enterica serovar Enteritidis
|
36.0
%
|
|
|
Inhibition of reconstituted Escherichia coli DNA gyrase subunit AB assessed as reduction of DNA supercoiling activity using pBR322 DNA substrate
|
Escherichia coli
|
300.0
nM
|
|
|
Inhibition of Escherichia coli DNA gyrase by gel electrophoresis
|
Escherichia coli
|
100.0
nM
|
|
|
Inhibition of DNA supercoiling activity of Escherichia coli DNA gyrase
|
Escherichia coli
|
450.0
nM
|
|
|
Inhibition of Escherichia coli DNA gyrase assessed as reduction of DNA supercoiling activity using pBR322 DNA substrate after 30 mins by electrophoresis
|
Escherichia coli
|
0.34
ug.mL-1
|
|
|
Inhibition of Escherichia coli topoisomerase 4 assessed as decatenation of kDNA after 30 mins by electrophoresis
|
Escherichia coli
|
4.6
ug.mL-1
|
|
|
Inhibition of Pseudomonas aeruginosa ATCC 27853 biofilm formation at 5 ug/ml after 24 hrs using crystal violet staining by spectrophotometry analysis
|
Pseudomonas aeruginosa
|
51.0
%
|
|
|
Antibacterial activity against Staphylococcus aureus ATCC 29213 by NCCLS method
|
Staphylococcus aureus
|
0.07
ug.mL-1
|
|
|
Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 by NCCLS method
|
Staphylococcus aureus
|
0.07
ug.mL-1
|
|
|
Antibacterial activity against Escherichia coli by NCCLS method
|
Escherichia coli
|
0.005
ug.mL-1
|
|
|
Antibacterial activity against Mycobacterium intracellular ATCC 23068 by alamar blue method
|
Mycobacterium intracellulare
|
0.3
ug.mL-1
|
|
|
Inhibition of Escherichia coli DNA gyrase assessed as DNA supercoiling using pUC19 as substrate after 30 mins by agarose gel electrophoresis
|
Escherichia coli
|
700.0
nM
|
|
|
Antimicrobial activity against Mycobacterium intracellular ATCC 23068 after 5 days by MABA assay
|
Mycobacterium intracellulare
|
420.0
nM
|
|
|
Inhibition of Escherichia coli DNA gyrase-mediated supercoiling of relaxed pBR322 DNA
|
Escherichia coli
|
800.0
nM
|
|
|
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7
|
Plasmodium falciparum
|
8.82
ug.mL-1
|
|
|
Inhibition of DNA supercoiling activity of Escherichia coli DNA gyrase after 1 hr by agarose gel electrophoresis
|
Escherichia coli
|
970.0
nM
|
|
|
Inhibition of DNA decatenation activity of Escherichia coli DNA topoisomerase 4 after 1 hr by agarose gel electrophoresis
|
Escherichia coli
|
392.0
nM
|
|
|
Antimicrobial activity against Staphylococcus aureus ATCC 29213 by CLSI method
|
Staphylococcus aureus
|
0.12
ug.mL-1
|
|
|
Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 by CLSI method
|
Staphylococcus aureus
|
0.09
ug.mL-1
|
|
|
Antimicrobial activity against Mycobacterium intracellulare ATCC 23068 by Franzblau method
|
Mycobacterium intracellulare
|
0.3
ug.mL-1
|
|
|
Antimicrobial activity against Escherichia coli ATCC 35218 by CLSI method
|
Escherichia coli
|
0.003
ug.mL-1
|
|
|
Antimicrobial activity against Pseudomonas aeruginosa PAO1 assessed as inhibition of cell viability after 18 hrs by spectrophotometry
|
Pseudomonas aeruginosa PAO1
|
38.0
nM
|
|
|
Inhibition of human ERG expressed in mammalian cells at 10 uM by patch clamp method
|
Homo sapiens
|
1.0
%
|
|
|
Binding affinity to rat cerebral cortex histamine H3 receptor
|
Rattus norvegicus
|
0.654
nM
|
|
|
Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591
|
Staphylococcus aureus
|
0.1
ug.mL-1
|
|
|
Antibacterial activity against Staphylococcus aureus ATCC 29213
|
Staphylococcus aureus
|
0.1
ug.mL-1
|
|
|
Antitubercular activity against Mycobacterium tuberculosis
|
Mycobacterium tuberculosis
|
0.5
ug.mL-1
|
|
|
Antibacterial activity against Mycobacterium intracellulare ATCC 23068 assessed as growth inhibition after 70 to 74 hr by Alamar blue assay
|
Mycobacterium intracellulare
|
0.32
ug.mL-1
|
|
|
Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as growth inhibition after 16 to 20 hr by Alamar blue assay
|
Pseudomonas aeruginosa
|
0.11
ug.mL-1
|
|
|
Antibacterial activity against Escherichia coli ATCC 35218 assessed as growth inhibition after 16 to 20 hr by Alamar blue assay
|
Escherichia coli
|
0.005
ug.mL-1
|
|
|
Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as growth inhibition after 16 to 20 hr by Alamar blue assay
|
Staphylococcus aureus
|
0.1
ug.mL-1
|
|
|
Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as growth inhibition after 16 to 20 hr by Alamar blue assay
|
Staphylococcus aureus
|
0.11
ug.mL-1
|
|
|
Antimicrobial activity against Vibrio cholerae assessed as growth inhibition after 24 hr by cup-plate method
|
Vibrio cholerae
|
200.0
nM
|
|
|
Antimicrobial activity against Pseudomonas aeruginosa NCIM 2967 assessed as growth inhibition after 24 hr by serial double dilution method
|
Pseudomonas aeruginosa
|
50.0
nM
|
|
|
Antimicrobial activity against Escherichia coli NCIM 2068 assessed as growth inhibition after 24 hr by serial double dilution method
|
Escherichia coli
|
30.0
nM
|
|
|
Inhibition of Mycobacterium leprae DNA gyrase GyrA/GyrB assessed as reduction of enzyme supercoiling activity using relaxed pBR322 DNA substrate incubated for 2 hrs at 30 degC by ethidium bromide based gel electrophoresis
|
Mycobacterium leprae
|
2.0
ug.mL-1
|
|
|
Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA/GyrB assessed as reduction of enzyme supercoiling activity using relaxed pBR322 DNA substrate incubated for 1 hr at 37 degC by ethidium bromide based gel electrophoresis
|
Mycobacterium tuberculosis
|
6.0
ug.mL-1
|
|
|
Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 by CLSI method
|
Staphylococcus aureus
|
390.0
nM
|
|
|
Antibacterial activity against Staphylococcus aureus ATCC 29213 by CLSI method
|
Staphylococcus aureus
|
390.0
nM
|
|
|
Inhibition of wild type Escherichia coli ATCC 25922 DNA gyrase subunit 2GyrA/2GyrB assessed as pBR322 supercoiling after 1 hr
|
Escherichia coli
|
500.0
nM
|
|
|
Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM
|
Cricetulus griseus
|
105.26
%
|
|
|
Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM
|
Cricetulus griseus
|
112.43
%
|
|
|
Antimicrobial activity against Mycobacterium intracellulare ATCC 23068 by Alamar blue method
|
Mycobacterium intracellulare
|
0.005
ug.mL-1
|
|
|
Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 by Alamar blue method
|
Staphylococcus aureus
|
0.11
ug.mL-1
|
|
|
Antimicrobial activity against Staphylococcus aureus ATCC 29213 by Alamar blue method
|
Staphylococcus aureus
|
0.14
ug.mL-1
|
|
|
Antimicrobial activity against methicillin-resistant Staphylococcus aureus by NCCLS method
|
Staphylococcus aureus
|
390.0
nM
|
|
|
Antimicrobial activity against Staphylococcus aureus by NCCLS method
|
Staphylococcus aureus
|
390.0
nM
|
|
|
Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as growth inhibition after 16-20 hrs by CLSI method
|
Staphylococcus aureus
|
0.09
ug.mL-1
|
|
|
Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as growth inhibition after 16-20 hrs by CLSI method
|
Staphylococcus aureus
|
0.08
ug.mL-1
|
|
|
Antibacterial activity against Staphylococcus aureus
|
Staphylococcus aureus
|
0.12
ug.mL-1
|
|
|
Antibacterial activity against methicillin-resistant Staphylococcus aureus
|
Staphylococcus aureus
|
0.09
ug.mL-1
|
|
|
Antibacterial activity against Mycobacterium intracellulare
|
Mycobacterium intracellulare
|
0.3
ug.mL-1
|
|
|
Antibacterial activity against Escherichia coli
|
Escherichia coli
|
0.003
ug.mL-1
|
|
|
Antibacterial activity against Staphylococcus aureus ATCC 25923 after 24 hrs by spectrophotometric analysis
|
Staphylococcus aureus
|
0.3
ug.mL-1
|
|
|
Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 700699 after 24 hrs by spectrophotometric analysis
|
Staphylococcus aureus
|
16.7
ug.mL-1
|
|
|
Antibacterial activity against Staphylococcus aureus ATCC 29213 after 24 hrs by spectrophotometric analysis
|
Staphylococcus aureus
|
16.7
ug.mL-1
|
|
|
Antibacterial activity against gentamicin-resistant Staphylococcus aureus ATCC 33592 after 24 hrs by spectrophotometric analysis
|
Staphylococcus aureus
|
0.2
ug.mL-1
|
|
|
Antibacterial activity against Escherichia coli after 24 hrs by spectrophotometric analysis
|
Escherichia coli
|
0.007
ug.mL-1
|
|
|
Antibacterial activity against Klebsiella pneumoniae after 24 hrs by spectrophotometric analysis
|
Klebsiella pneumoniae
|
0.02
ug.mL-1
|
|
|
Antibacterial activity against Staphylococcus aureus ATCC 29213 by CLSI method
|
Staphylococcus aureus
|
0.08
ug.mL-1
|
|
|
Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 after 16 to 20 hrs by CLSI method
|
Staphylococcus aureus
|
0.09
ug.mL-1
|
|
|
Anti-biofilm activity against Staphylococcus aureus MTCC 96 assessed as inhibition of biofilm formation incubated for 24 hrs by crystal violet staining based modified biofilm inhibition assay
|
Staphylococcus aureus
|
990.0
nM
|
|
|
Inhibition of Escherichia coli DNA gyrase using fluorescence-tagged DNA by fluorescenct polarization assay
|
Escherichia coli
|
270.0
nM
|
|
|
Inhibition of Escherichia coli DNA gyrase assessed as supercoiled plasmid DNA formation after 30 mins by electrophoretic analysis
|
Escherichia coli
|
200.0
nM
|
|
|
Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as growth inhibition
|
Staphylococcus aureus
|
0.08
ug.mL-1
|
|
|
Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as growth inhibition
|
Staphylococcus aureus
|
0.09
ug.mL-1
|
|
|
Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 33591
|
Staphylococcus aureus
|
0.1
ug.mL-1
|
|
|
Antimicrobial activity against Staphylococcus aureus ATCC 29213
|
Staphylococcus aureus
|
0.1
ug.mL-1
|
|
|
Inhibition of Escherichia coli DNA gyrase after 1 hr by agarose gel electrophoresis
|
Escherichia coli
|
150.0
nM
|
|
|
Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as growth inhibition using fresh sample in DMSO by CLSI method
|
Staphylococcus aureus
|
0.1
ug.mL-1
|
|
|
Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as growth inhibition using fresh sample in DMSO by CLSI method
|
Staphylococcus aureus
|
0.1
ug.mL-1
|
|
|
Antibacterial activity against methicillin-resistant Staphylococcus aureus EAMC30 assessed as growth inhibition using fresh sample in DMSO by CLSI method
|
Staphylococcus aureus
|
29.4
ug.mL-1
|
|
|
Antibacterial activity against Enterococcus faecalis ATCC 29212 assessed as growth inhibition using fresh sample in DMSO by CLSI method
|
Enterococcus faecalis ATCC 29212
|
0.2
ug.mL-1
|
|
|
Antibacterial activity against Enterococcus faecalis ATCC 51299 assessed as growth inhibition using fresh sample in DMSO by CLSI method
|
Enterococcus faecalis
|
0.2
ug.mL-1
|
|
|
Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 6 days by MTT assay
|
Mycobacterium tuberculosis H37Rv
|
600.0
nM
|
|
|
Inhibition of Escherichia coli recombinant gyrase A2B2 assessed as reduction of pHOT-1 supercoiling after 90 mins
|
Escherichia coli
|
460.0
nM
|
|
|
Inhibition of biofilm formation in Staphylococcus epidermidis ATCC 12228 after 24 hrs using MTT staining by spectrophotometer analysis
|
Staphylococcus epidermidis
|
7.0
ug.mL-1
|
|
|
Inhibition of biofilm formation in Staphylococcus epidermidis ATCC 35984 after 24 hrs using MTT staining by spectrophotometer analysis
|
Staphylococcus epidermidis
|
11.59
ug.mL-1
|
|
|
Inhibition of biofilm formation in Staphylococcus epidermidis 16/04 after 24 hrs using MTT staining by spectrophotometer analysis
|
Staphylococcus epidermidis
|
6.81
ug.mL-1
|
|
|
Inhibition of biofilm formation in Staphylococcus epidermidis 23/04 after 24 hrs using MTT staining by spectrophotometer analysis
|
Staphylococcus epidermidis
|
42.76
ug.mL-1
|
|
|
Inhibition of biofilm formation in Staphylococcus epidermidis 24/04 after 24 hrs using MTT staining by spectrophotometer analysis
|
Staphylococcus epidermidis
|
12.95
ug.mL-1
|
|
|
Inhibition of biofilm formation in Staphylococcus epidermidis 31/04 after 24 hrs using MTT staining by spectrophotometer analysis
|
Staphylococcus epidermidis
|
22.13
ug.mL-1
|
|
|
Inhibition of biofilm formation in Staphylococcus epidermidis 62/04 after 24 hrs using MTT staining by spectrophotometer analysis
|
Staphylococcus epidermidis
|
4.81
ug.mL-1
|
|
|
Inhibition of biofilm formation in Staphylococcus epidermidis 63/04 after 24 hrs using MTT staining by spectrophotometer analysis
|
Staphylococcus epidermidis
|
7.14
ug.mL-1
|
|
|
Inhibition of biofilm formation in Staphylococcus epidermidis 76/04 after 24 hrs using MTT staining by spectrophotometer analysis
|
Staphylococcus epidermidis
|
7.93
ug.mL-1
|
|
|
Inhibition of biofilm formation in Staphylococcus epidermidis 151/04 after 24 hrs using MTT staining by spectrophotometer analysis
|
Staphylococcus epidermidis
|
13.1
ug.mL-1
|
|
|
Inhibition of biofilm formation in Staphylococcus epidermidis ATCC 12228 at 4 ug/ml after 24 hrs using MTT staining by spectrophotometer analysis
|
Staphylococcus epidermidis
|
21.3
%
|
|
|
Inhibition of biofilm formation in Staphylococcus epidermidis ATCC 35984 at 4 ug/ml after 24 hrs using MTT staining by spectrophotometer analysis
|
Staphylococcus epidermidis
|
45.43
%
|
|
|
Inhibition of biofilm formation in Staphylococcus epidermidis 16/04 at 4 ug/ml after 24 hrs using MTT staining by spectrophotometer analysis
|
Staphylococcus epidermidis
|
41.96
%
|
|
|
Inhibition of biofilm formation in Staphylococcus epidermidis 23/04 at 4 ug/ml after 24 hrs using MTT staining by spectrophotometer analysis
|
Staphylococcus epidermidis
|
5.71
%
|
|
|
Inhibition of biofilm formation in Staphylococcus epidermidis 31/04 at 4 ug/ml after 24 hrs using MTT staining by spectrophotometer analysis
|
Staphylococcus epidermidis
|
18.66
%
|
|
|
Inhibition of biofilm formation in Staphylococcus epidermidis 62/04 at 4 ug/ml after 24 hrs using MTT staining by spectrophotometer analysis
|
Staphylococcus epidermidis
|
59.89
%
|
|
|
Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 after 18 to 24 hrs by spectrophotometric analysis
|
Staphylococcus aureus
|
0.2
ug.mL-1
|
|
|
Antibacterial activity against methicillin-resistant Staphylococcus aureus CIMRSA1 after 18 to 24 hrs by spectrophotometric analysis
|
Staphylococcus aureus
|
10.4
ug.mL-1
|
|
|
Antibacterial activity against methicillin-resistant Staphylococcus aureus CIMRSA2 after 18 to 24 hrs by spectrophotometric analysis
|
Staphylococcus aureus
|
2.9
ug.mL-1
|
|
|
Antibacterial activity against methicillin-resistant Staphylococcus aureus CIMRSA3 after 18 to 24 hrs by spectrophotometric analysis
|
Staphylococcus aureus
|
4.4
ug.mL-1
|
|
|
Antibacterial activity against methicillin-resistant Staphylococcus aureus CIMRSA4 after 18 to 24 hrs by spectrophotometric analysis
|
Staphylococcus aureus
|
2.0
ug.mL-1
|
|
|
Antibacterial activity against methicillin-resistant Staphylococcus aureus CIMRSA5 after 18 to 24 hrs by spectrophotometric analysis
|
Staphylococcus aureus
|
5.3
ug.mL-1
|
|
|
Antibacterial activity against methicillin-resistant Staphylococcus aureus CIMRSA6 after 18 to 24 hrs by spectrophotometric analysis
|
Staphylococcus aureus
|
2.5
ug.mL-1
|
|
|
Antibacterial activity against methicillin-resistant Staphylococcus aureus CIMRSA7 after 18 to 24 hrs by spectrophotometric analysis
|
Staphylococcus aureus
|
0.39
ug.mL-1
|
|
|
Antibacterial activity against Escherichia coli ATCC 25922 after 18 to 24 hrs by spectrophotometric analysis
|
Escherichia coli ATCC 25922
|
0.008
ug.mL-1
|
|
|
Antibiofilm activity against Staphylococcus aureus MLS-16 MTCC 2940 after 24 hrs by crystal violet staining method
|
Staphylococcus aureus
|
0.4
ug.mL-1
|
|
|
Antibiofilm activity against Escherichia coli MTCC 739 after 24 hrs by crystal violet staining method
|
Escherichia coli
|
0.5
ug.mL-1
|
|
|
Antibiofilm activity against Micrococcus luteus MTCC 2470 after 24 hrs by crystal violet staining based method
|
Micrococcus luteus
|
500.0
nM
|
|
|
Antibiofilm activity against Staphylococcus aureus MTCC 96 after 24 hrs by crystal violet staining based method
|
Staphylococcus aureus
|
300.0
nM
|
|
|
Antibiofilm activity against Staphylococcus aureus MLS-16 MTCC 2940 after 24 hrs by crystal violet staining based method
|
Staphylococcus aureus
|
400.0
nM
|
|
|
Antibiofilm activity against Bacillus subtilis MTCC 121 after 24 hrs by well diffusion assay by crystal violet staining based method
|
Bacillus subtilis
|
500.0
nM
|
|
|
Antibiofilm activity against Bacillus subtilis MTCC 121 after 24 hrs by crystal violet staining method
|
Bacillus subtilis
|
0.7
ug.mL-1
|
|
|
Antibiofilm activity against Staphylococcus aureus MTCC 96 after 24 hrs by crystal violet staining method
|
Staphylococcus aureus
|
0.6
ug.mL-1
|
|
|
Antibiofilm activity against Staphylococcus aureus MTCC 96 after 24 hrs by crystal violet staining based assay
|
Staphylococcus aureus
|
0.6
ug.mL-1
|
|
|
Antibiofilm activity against Bacillus subtilis MTCC 121 after 24 hrs by crystal violet staining based assay
|
Bacillus subtilis
|
0.5
ug.mL-1
|
|
|
Antibiofilm activity against Staphylococcus aureus MLS16 MTCC 2940 after 24 hrs by crystal violet staining based assay
|
Staphylococcus aureus
|
0.4
ug.mL-1
|
|
|
Antibiofilm activity against Micrococcus luteus MTCC 2470 after 24 hrs by crystal violet staining based assay
|
Micrococcus luteus
|
0.6
ug.mL-1
|
|
|
Antibiofilm activity against Bacillus subtilis MTCC 121 after 24 hrs by crystal violet staining based assay
|
Bacillus subtilis
|
500.0
nM
|
|
|
Antibiofilm activity against Staphylococcus aureus MTCC 96 after 24 hrs by crystal violet staining based assay
|
Staphylococcus aureus
|
700.0
nM
|
|
|
Antibiofilm activity against Staphylococcus aureus MLS16 MTCC 2940 after 24 hrs by crystal violet staining based assay
|
Staphylococcus aureus
|
600.0
nM
|
|
|
Antibiofilm activity against Micrococcus luteus MTCC 2470 after 24 hrs by crystal violet staining based assay
|
Micrococcus luteus
|
800.0
nM
|
|
|
Antibiofilm activity against Klebsiella planticola MTCC 530 after 24 hrs by crystal violet staining based assay
|
Raoultella planticola
|
600.0
nM
|
|
|
Antitubercular activity against Mycobacterium tuberculosis H37Ra ATCC 25177 at 10 uM relative to control
|
Mycobacterium tuberculosis H37Ra
|
99.7
%
|
|
|
Antitubercular activity against Mycobacterium tuberculosis H37Ra ATCC 25177 at 1 uM relative to control
|
Mycobacterium tuberculosis H37Ra
|
99.6
%
|
|
|
Antibiofilm activity against Staphylococcus aureus MTCC 96 incubated for 24 hrs by crystal violet staining-based assay
|
Staphylococcus aureus
|
0.6
ug.mL-1
|
|
|
Antibiofilm activity against Bacillus subtilis MTCC 121 incubated for 24 hrs by crystal violet staining-based assay
|
Bacillus subtilis
|
0.5
ug.mL-1
|
|
|
Antibiofilm activity against Staphylococcus aureus MLS16 MTCC 2940 incubated for 24 hrs by crystal violet staining-based assay
|
Staphylococcus aureus
|
0.4
ug.mL-1
|
|
|
Antibiofilm activity against Micrococcus luteus MTCC 2470 incubated for 24 hrs by crystal violet staining-based assay
|
Micrococcus luteus
|
0.4
ug.mL-1
|
|
|
Antimicrobial activity against Staphylococcus aureus ATCC 29213 by broth microdilution method
|
Staphylococcus aureus
|
300.0
nM
|
|
|
Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 by broth microdilution method
|
Staphylococcus aureus
|
200.0
nM
|
|
|
Antibacterial activity against Enterococcus faecium DSM 20477 after 18 hrs
|
Enterococcus faecium
|
2.29
ug.mL-1
|
|
|
Antibacterial activity against Escherichia coli DSM 1116 after 18 hrs
|
Escherichia coli
|
0.01
ug.mL-1
|
|
|
Antibacterial activity against Acinetobacter baumannii DSM 30007 after 18 hrs
|
Acinetobacter baumannii
|
0.2
ug.mL-1
|
|
|
Antibacterial activity against Klebsiella pneumoniae DSM 11678 after 18 hrs
|
Klebsiella pneumoniae
|
0.05
ug.mL-1
|
|
|
Antimalarial activity against chloroquine-sensitive Plasmodium falciparum MRC-2 schizont infected in RBC measured after 24 to 30 hrs hrs by giemsa staining based light microscopic method
|
Plasmodium falciparum
|
50.0
nM
|
|
|
Antimalarial activity against chloroquine-resistant Plasmodium falciparum RKL-9 schizont infected in RBC measured after 24 to 30 hrs hrs by giemsa staining based light microscopic method
|
Plasmodium falciparum
|
401.0
nM
|
|
|
Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 24 hrs by MTT assay
|
Mus musculus
|
305.77
ug.mL-1
|
|
|
Antibiofilm activity against Staphylococcus aureus MTCC 96 after 24 hrs by crystal violet staining based assay
|
Staphylococcus aureus
|
0.6
ug.mL-1
|
|
|
Antibiofilm activity against Bacillus subtilis MTCC 121 after 24 hrs by crystal violet staining based assay
|
Bacillus subtilis
|
0.5
ug.mL-1
|
|
|
Antibiofilm activity against Staphylococcus aureus MLS16 MTCC 2940 after 24 hrs by crystal violet staining based assay
|
Staphylococcus aureus
|
0.4
ug.mL-1
|
|
|
Antibiofilm activity against Micrococcus luteus MTCC 2470 after 24 hrs by crystal violet staining based assay
|
Micrococcus luteus
|
0.4
ug.mL-1
|
|
|
Antibacterial activity against Staphylococcus aureus ATCC 29213 after 70 to 74 hrs by alamar blue dye based CLSI method
|
Staphylococcus aureus
|
0.08
ug.mL-1
|
|
|
Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 after 16 to 20 hrs by alamar blue dye based CLSI method
|
Staphylococcus aureus
|
0.09
ug.mL-1
|
|
|
Antibiofilm activity against Staphylococcus aureus MTCC 96 after 24 hrs by crystal violet staining based method
|
Staphylococcus aureus
|
700.0
nM
|
|
|
Antibiofilm activity against Bacillus subtilis MTCC 121 after 24 hrs by crystal violet staining based method
|
Bacillus subtilis
|
600.0
nM
|
|
|
Antibiofilm activity against Staphylococcus aureus MLS16 MTCC 2940 after 24 hrs by crystal violet staining based method
|
Staphylococcus aureus
|
700.0
nM
|
|
|
Antibiofilm activity against Micrococcus luteus MTCC 2470 after 24 hrs by crystal violet staining based method
|
Micrococcus luteus
|
800.0
nM
|
|
|
Antibiofilm activity against Escherichia coli MTCC 739 after 24 hrs by crystal violet staining based method
|
Escherichia coli
|
800.0
nM
|
|
|
Antibiofilm activity against Klebsiella planticola MTCC 530 after 24 hrs by crystal violet staining based method
|
Raoultella planticola
|
600.0
nM
|
|
|
Anti-bacterial activity against Mycobacterium intracellulare ATCC 23068 after 68 to 72 hrs by Alamar blue assay
|
Mycobacterium intracellulare
|
0.47
ug.mL-1
|
|
|
Anti-bacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 by CLSI method
|
Staphylococcus aureus
|
0.14
ug.mL-1
|
|
|
Anti-bacterial activity against Staphylococcus aureus ATCC 29213 by CLSI method
|
Staphylococcus aureus
|
0.13
ug.mL-1
|
|
|
Anti-bacterial activity against Escherichia coli ATCC 35218 by CLSI method
|
Escherichia coli
|
0.007
ug.mL-1
|
|
|
Anti-bacterial activity against Pseudomonas aeruginosa ATCC 27853 by CLSI method
|
Pseudomonas aeruginosa
|
0.09
ug.mL-1
|
|
|
Inhibition of Escherichia coli N-terminal His6-tagged DNA gyrase subunit GyrA/GyrB supercoiling activity expressed in Escherichia coli BL21 (DE3) using relaxed pBR322 DNA as substrate after 1 hr by agarose gel electrophoresis
|
Escherichia coli
|
500.0
nM
|
|
|
Inhibition of wild-type Pseudomonas aeruginosa DNA gyrase supercoiling activity using relaxed pBR322 DNA as substrate by ethidium bromide based agarose gel electrophoresis
|
Pseudomonas aeruginosa
|
500.0
nM
|
|
|
Antibacterial activity against Escherichia coli NCTC 10419 infected in CF mouse assessed as protection against bacterial infection administered orally at 1 and 4 hrs post infection measured after 1 week
|
Escherichia coli
|
1.25
mg kg-1
|
|
|
Inhibition of Staphylococcus aureus DNA gyrase subunit A supercoiling activity using relaxed pBR322 DNA as substrate after 60 mins by agarose gel electrophoresis
|
Staphylococcus aureus
|
4.95
ug.mL-1
|
|
|
Inhibition of Staphylococcus aureus DNA gyrase supercoiling activity using pBR322 DNA as substrate after 30 mins by ethidium bromide staining based agarose gel electrophoresis method
|
Staphylococcus aureus
|
3.5
ug.mL-1
|
|
|
Inhibition of Staphylococcus aureus DNA topoisomerase 4 using Kinetoplast DNA as substrate after 30 mins by ethidium bromide staining based agarose gel electrophoresis method
|
Staphylococcus aureus
|
1.7
ug.mL-1
|
|
|
Inhibition of Escherichia coli DNA gyrase A2B2 using relaxed pNO1 as substrate
|
Escherichia coli
|
310.0
nM
|
|
|
Inhibition of His tagged Escherichia coli ATCC 25922 DNA gyrase A expressed in Escherichia coli BL21 (DE3) pLysS cells assessed as reduction in enzyme-mediated supercoiling of relaxed plasmid DNA pNO1 after 30 mins in presence of biotinylated TFO1 by fluorescence assay
|
Escherichia coli ATCC 25922
|
190.0
nM
|
|
|
In vivo antibacterial activity against Escherichia coli NCTC 10419 infected in po dosed mouse administered at 1 and 4 hrs post infection
|
Escherichia coli
|
1.25
mg kg-1
|
|
|
Antibiofilm activity against Bacillus subtilis MTCC 121 after 24 hrs by crystal violet staining-based assay
|
Bacillus subtilis
|
0.23
ug.mL-1
|
|
|
Antibiofilm activity against Staphylococcus aureus MTCC 96 after 24 hrs by crystal violet staining-based assay
|
Staphylococcus aureus
|
0.21
ug.mL-1
|
|
|
Antibiofilm activity against Staphylococcus aureus MLS16 MTCC 2940 after 24 hrs by crystal violet staining-based assay
|
Staphylococcus aureus
|
0.24
ug.mL-1
|
|
|
Antibiofilm activity against Pseudomonas aeruginosa MTCC 2453 after 24 hrs by crystal violet staining-based assay
|
Pseudomonas aeruginosa
|
0.32
ug.mL-1
|
|
|
Antibiofilm activity against Klebsiella planticola MTCC 530 after 24 hrs by crystal violet staining-based assay
|
Raoultella planticola
|
0.29
ug.mL-1
|
|
|
Antimicrobial activity against methicillin-resistant Staphylococcus aureus by modified CLSI based method
|
Staphylococcus aureus
|
0.12
ug.mL-1
|
|
|
Antimicrobial activity against Staphylococcus aureus by modified CLSI based method
|
Staphylococcus aureus
|
0.11
ug.mL-1
|
|
|
Inhibition of Escherichia coli DNA gyrase assessed as inhibition of pUC19 supercoiling after 30 mins by agarose gel electrophoresis
|
Escherichia coli
|
170.0
nM
|
|
|
Inhibition of Escherichia coli DNA topoisomerase-2 mediated DNA relaxation using supercoiled pBR322 plasmid DNA as substrate after 60 mins by ethidium bromide staining based agarose gel electrophoresis
|
Escherichia coli
|
0.5
ug.mL-1
|
|
|
Inhibition of Escherichia coli DNA topoisomerase-4 mediated decatenation using kinetoplast DNA as substrate after 30 mins agarose gel electrophoresis method
|
Escherichia coli
|
8.0
ug.mL-1
|
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging
|
Homo sapiens
|
2.89
%
|
|
|
Antimicrobial activity against Candida albicans ATCC 90028 assessed as inhibition of microbial growth by CLSI based method
|
Candida albicans
|
30.0
nM
|
|
|
Antimicrobial activity against Aspergillus fumigatus ATCC 90906 assessed as inhibition of microbial growth by CLSI based method
|
Aspergillus fumigatus
|
30.0
nM
|
|
|
Antimicrobial activity against Cryptococcus neoformans ATCC 90113 assessed as inhibition of microbial growth by CLSI based method
|
Cryptococcus neoformans
|
30.0
nM
|
|
|
Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 assessed as inhibition of microbial growth by CLSI based method
|
Staphylococcus aureus
|
30.0
nM
|
|
|
Antimicrobial activity against Escherichia coli ATCC 35218 assessed as inhibition of microbial growth by CLSI based method
|
Escherichia coli
|
0.03
nM
|
|
|
Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 assessed as inhibition of microbial growth by CLSI based method
|
Pseudomonas aeruginosa
|
0.3
nM
|
|
|
Antibacterial activity against Klebsiella pneumoniae ATCC 13883 incubated for 24 hrs by resazurin dye based fluorimetric assay
|
Klebsiella pneumoniae
|
250.0
nM
|
|
|
Inhibition of Escherichia coli DNA gyrase super-coiling activity using relaxed pNO1 DNA as substrate incubated for 30 mins by fluorescence assay
|
Escherichia coli
|
122.0
nM
|
|
|
Antibacterial activity against Escherichia coli K-12 BW25113 incubated for 18 hrs by broth microdilution method
|
Escherichia coli
|
22.0
nM
|
|
|
Antibacterial activity against Staphylococcus aureus SH1000 incubated for 18 hrs by broth microdilution method
|
Staphylococcus aureus
|
350.0
nM
|
|
|
Inhibition of Escherichia coli DNA gyrase (A2B2 tetramer) using relaxed pBR322 as substrate preincubated for 30 mins followed by enzyme addition by SYBR staining-based agarose gel electrophoresis method
|
Escherichia coli
|
280.0
nM
|
|
|
Antibiofilm activity against Bacillus subtilis MTCC 121 assessed as inhibition of biofilm formation by crystal violet staining-based microtitre plate assay
|
Bacillus subtilis
|
6.6
ug.mL-1
|
|
|
Antibiofilm activity against Staphylococcus aureus MLS-16 MTCC 2940 assessed as inhibition of biofilm formation by crystal violet staining-based microtitre plate assay
|
Staphylococcus aureus
|
6.6
ug.mL-1
|
|
|
Antibiofilm activity against Micrococcus luteus MTCC 2470 assessed as inhibition of biofilm formation by crystal violet staining-based microtitre plate assay
|
Micrococcus luteus
|
6.8
ug.mL-1
|
|
|
Antibiofilm activity against Staphylococcus aureus MTCC 96 assessed as inhibition of biofilm formation by crystal violet staining-based microtitre plate assay
|
Staphylococcus aureus
|
6.7
ug.mL-1
|
|
|
Antibiofilm activity against Escherichia coli MTCC 739 assessed as inhibition of biofilm formation by crystal violet staining-based microtitre plate assay
|
Escherichia coli
|
7.3
ug.mL-1
|
|
|
Antibiofilm activity against Pseudomonas aeruginosa MTCC 2453 assessed as inhibition of biofilm formation by crystal violet staining-based microtitre plate assay
|
Pseudomonas aeruginosa
|
7.4
ug.mL-1
|
|
|
Antibiofilm activity against Klebsiella planticola MTCC 530 assessed as inhibition of biofilm formation by crystal violet staining-based microtitre plate assay
|
Raoultella planticola
|
8.6
ug.mL-1
|
|
|
Cytotoxicity against human MRC5 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay
|
Homo sapiens
|
53.4
ug.mL-1
|
|
|
Antibiofilm activity against Escherichia coli MTCC 739 assessed as inhibition of biofilm formation incubated for 48 hrs in presence of Staphylococcus aureus MTCC 96 by FE-SEM analysis
|
Escherichia coli
|
11.6
ug.mL-1
|
|
|
Antibiofilm activity against Staphylococcus aureus MTCC 96 assessed as inhibition of biofilm formation incubated for 48 hrs in presence of Escherichia coli MTCC 739 by FE-SEM analysis
|
Staphylococcus aureus
|
11.6
ug.mL-1
|
|
|
Antibiofilm activity against ofloxacin-resistant Bacillus megaterium assessed as disruption of biofilm at 200 ug/ml after 24 hrs by crystal violet staining based ELISA relative to control
|
Bacillus megaterium
|
56.3
%
|
|
|
Antibiofilm activity against tetracycline-resistant Bacillus subtilis assessed as disruption of biofilm at 200 ug/ml after 24 hrs by crystal violet staining based ELISA relative to control
|
Bacillus subtilis
|
23.0
%
|
|
|
Antibiofilm activity against carbapenem-resistant Escherichia coli assessed as disruption of biofilm at 200 ug/ml after 24 hrs by crystal violet staining based ELISA relative to control
|
Escherichia coli
|
45.0
%
|
|
|
Antibiofilm activity against tetracycline-resistant Pseudomonas fluorescens assessed as disruption of biofilm at 200 ug/ml after 24 hrs by crystal violet staining based ELISA relative to control
|
Pseudomonas fluorescens
|
38.0
%
|
|
|
Antibiofilm activity against carbenicillin-resistant Pseudomonas aeruginosa assessed as disruption of biofilm at 200 ug/ml after 24 hrs by crystal violet staining based ELISA relative to control
|
Pseudomonas aeruginosa
|
49.7
%
|
|
|
Antibiofilm activity against carbapenem-resistant Klebsiella pneumoniae assessed as disruption of biofilm at 200 ug/ml after 24 hrs by crystal violet staining based ELISA relative to control
|
Klebsiella pneumoniae
|
25.5
%
|
|
|
Antibiofilm activity against tetracycline-resistant Klebsiella pneumoniae assessed as disruption of biofilm at 200 ug/ml after 24 hrs by crystal violet staining based ELISA relative to control
|
Klebsiella pneumoniae
|
43.0
%
|
|
|
Inhibition of Escherichia coli JMtacA/JMtacB DNA gyrase subunit A2B2 S83W mutant using relaxed pBR322 DNA as substrate incubated for 30 mins in presence of ATP by ethidium bromide staining based agarose gel electrophoresis
|
Escherichia coli
|
500.0
nM
|
|
|
Cytotoxicity against human HepG2 cells after 24 hrs by cell titre-glo assay
|
Homo sapiens
|
128.0
ug.mL-1
|
|
|
Inhibition of human ERG channel at 100 uM by automated patch clamp assay
|
Homo sapiens
|
28.0
%
|
|
|
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate
|
Severe acute respiratory syndrome coronavirus 2
|
16.68
%
|
|
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate
|
Severe acute respiratory syndrome coronavirus 2
|
13.11
%
|
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.08
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.14
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.08
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
0.14
%
|
|
|
Inhibition of Staphylococcus aureus DNA gyrase using relaxed pNO1 as substrate by gel based fluorescence assay
|
Staphylococcus aureus
|
13.05
ug.mL-1
|
|
|
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
|
Homo sapiens
|
302.0
nM
|
|
|
Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay
|
Homo sapiens
|
302.0
nM
|
|
|
Inhibition of recombinant full-length C-terminal His6-tagged Escherichia coli DNA gyrase AB supercoiling activity using relaxed DNA as substrate preincubated for 30 mins followed by substrate addition and measured after 2 hrs in presence of ATP by size exclusion HPLC analysis
|
Escherichia coli
|
490.0
nM
|
|
|
Inhibition of Escherichia coli DNA gyrase using relaxed PBR322 plasmid DNA as substrate incubated for 30 mins by ethidium bromide staining based agarose gel electrophoresis method
|
Escherichia coli
|
200.0
nM
|
|
|
Inhibition of biofilm formation in Pseudomonas aeruginosa MTCC 2453 incubated for 24 hrs by crystal violet staining based microtiter plate method
|
Pseudomonas aeruginosa
|
500.0
nM
|
|
|
Inhibition of biofilm formation in Escherichia coli MTCC 739 incubated for 24 hrs by crystal violet staining based microtiter plate method
|
Escherichia coli
|
600.0
nM
|
|
|
Inhibition of biofilm formation in Klebsiella planticola MTCC 530 incubated for 24 hrs by crystal violet staining based microtiter plate method
|
Raoultella planticola
|
800.0
nM
|
|
|
Inhibition of biofilm formation in Micrococcus luteus MTCC 2470 incubated for 24 hrs by crystal violet staining based microtiter plate method
|
Micrococcus luteus
|
800.0
nM
|
|
|
Inhibition of biofilm formation in Bacillus subtilis MTCC 121 incubated for 24 hrs by crystal violet staining based microtiter plate method
|
Bacillus subtilis
|
700.0
nM
|
|
|
Inhibition of biofilm formation in Staphylococcus aureus MLS16 MTCC 2940 incubated for 24 hrs by crystal violet staining based microtiter plate method
|
Staphylococcus aureus
|
700.0
nM
|
|
|
Inhibition of biofilm formation in Staphylococcus aureus MTCC 92 incubated for 24 hrs by crystal violet staining based microtiter plate method
|
Staphylococcus aureus
|
600.0
nM
|
|
|
Inhibition of Escherichia coli DNA gyrase using relaxed DNA as substrate incubated for 15 mins by ethidium bromide-based agarose gel electrophoresis
|
Escherichia coli
|
440.0
nM
|
|
|
Antibacterial activity against Salmonella enterica MTCC 3224 incubated overnight by broth dilution technique
|
Salmonella enterica
|
0.012
ug.mL-1
|
|
|
Antibacterial activity against Pseudomonas aeruginosa MTCC 2453 incubated overnight by broth dilution technique
|
Pseudomonas aeruginosa
|
0.012
ug.mL-1
|
|
|
Antibacterial activity against Enterococcus faecalis MTCC 439 incubated overnight by broth dilution technique
|
Enterococcus faecalis
|
0.012
ug.mL-1
|
|
|
Antibacterial activity against Streptococcus pneumoniae MTCC 655 incubated overnight by broth dilution technique
|
Streptococcus pneumoniae
|
0.012
ug.mL-1
|
|
|
Antibacterial activity against Klebsiella pneumoniae ATCC 700603 incubated overnight by broth dilution technique
|
Klebsiella pneumoniae
|
0.012
ug.mL-1
|
|
|
Antibacterial activity against Escherichia coli ATCC 25922 incubated overnight by broth dilution technique
|
Escherichia coli
|
0.012
ug.mL-1
|
|
|
Inhibition of DNA synthesis in Staphylococcus aureus ATCC 29213 at 8 times MIC measured by liquid scintillation counter
|
Staphylococcus aureus
|
86.2
%
|
|
|
Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 assessed as inhibition of bacterial growth by CLSI method
|
Staphylococcus aureus
|
0.09
ug.mL-1
|
|
|
Antibacterial activity against vancomycin resistant Enterococcus ATCC MP-1 assessed as inhibition of bacterial growth by CLSI method
|
Enterococcus
|
0.15
ug.mL-1
|
|
|
Antibacterial activity against Escherichia coli ATCC 35218 assessed as inhibition of bacterial growth by CLSI method
|
Escherichia coli
|
0.007
ug.mL-1
|
|
|
Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as inhibition of bacterial growth by CLSI method
|
Pseudomonas aeruginosa
|
0.09
ug.mL-1
|
|
|
Inhibition of Staphylococcus aureus topoisomerase 4 assessed as reduction in decatenation using kDNA as substrate incubated for 30 mins by fluorimetric assay
|
Staphylococcus aureus
|
550.0
nM
|
|
|
Inhibition of Escherichia coli DNA gyrase supercoiling activity using pBR322 as substrate incubated for 30 mins by fluorimetric assay
|
Escherichia coli
|
830.0
nM
|
|
